Advanced MR techniques in multicenter clinical trials

Journal of Magnetic Resonance Imaging

Volumn 37, Issue 4, 2013, Pages 761-769

  Ashton, Edward ^a   Riek, Jonathan ^a  

^a VirtualScopics LLC   (United States)

Author keywords

clinical trials; DCE MRI; protocol design; standardization; T2

Indexed keywords

GADOLINIUM;

BLOOD FLOW; BLOOD VESSEL PERMEABILITY; CLINICAL TRIAL (TOPIC); HUMAN; MEDICAL EDUCATION; MEDICAL RESEARCH; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PEER REVIEW; PRIORITY JOURNAL; REVIEW;

ACADEMIES AND INSTITUTES; CAPILLARY PERMEABILITY; CARTILAGE, ARTICULAR; CLINICAL PROTOCOLS; COLLAGEN; COMMUNITY HEALTH CENTERS; CONTRAST MEDIA; DIFFUSION OF INNOVATION; FORECASTING; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INSERVICE TRAINING; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; REGIONAL BLOOD FLOW; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84875462233     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23799     Document Type: Review

References (60)

1. Harris J, Frank J, Patronas N, McFarlin D, McFarland H,. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991; 29: 548-555.
2. Paty D, Li D,. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-667. (Pubitemid 23121952)
3. Miller D, Khan O, Sheremata W, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23. (Pubitemid 36026342)
4. Liu G, Rugo H, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005; 23: 5464-5473.
5. Mross K, Drevs J, Muller M, et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumors. Eur J Cancer 2005; 41: 1291-1299. (Pubitemid 40813005)
6. Kapur S, Remington G, Jones C, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996; 153: 948-950. (Pubitemid 26225470)
7. Moresco R, Cavallaro R, Messa C, et al. Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine. J Psychopharmacol 2004; 18: 355-365. (Pubitemid 39382563)
8. Herbst R, Onn A, Sandler A,. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005; 23: 3243-3256. (Pubitemid 46211349)
9. Anderson H, Yap J, Miller M, Robbins A, Jones T, Price P,. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003; 21: 2823-2830. (Pubitemid 46621829)
10. Therasse P, Arbuck E, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
11. Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guidelines (version 1.1). Eur J Cancer 2009; 45: 228-247.
12. Cheson B, Horning S, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-1253. (Pubitemid 29162950)
13. Cheson B, Pfistner B, Juweid M, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586. (Pubitemid 350002966)
14. Sharp J, Lidsky M, Collins L, Moreland J,. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971; 14: 706-720.
15. Phan T, Donnan G, Davis S, Byrnes G,. Proof-of-principle phase II MRI studies in stroke: sample size estimates from dichotomous and continuous data. Stroke 2006; 37: 2521-2525. (Pubitemid 44454672)
16. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36: 66-73. (Pubitemid 40054177)
17. Toh H, Yong W, Wong Y, et al. Phase 2 trials of linifanib (ABT-869) in advanced hepatocellular, renal cell and non-small cell lung cancer: associations of response by CT or DCE-MRI with patient outcome. Mol Cancer Ther 2009; 8 (Suppl): A105.
18. Jack C, Bernstein M, Fox N, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008; 27: 685-691. (Pubitemid 351508080)
19. Eckstein F, Maschek S, Wirth W, et al. One year change of knee cartilage morphology in the first release of participants from the Osteoarthritis Initiative progression subcohort: association with sex, body mass index, symptoms and radiographic osteoarthritis status. Ann Rheum Dis 2009; 68: 674-679.
20. Ashton E,. Early DCE-MRI findings predict tumor volume changes. In: Proceedings of the 17th Annual Meeting of ISMRM, Honolulu, 2009. (abstract 806).
21. Dunn TC, Lu Y, Jin H, Ries MD, Majumdar S,. T2 relaxation time of cartilage at MR imaging: comparison with severity of knee osteoarthritis. Radiology 2004; 232: 592-598. (Pubitemid 38971304)
22. Stahl R, Blumenkrantz G, Carballido-Gamio J, et al. MRI-derived T2 relaxation times and cartilage morphometry of the tibio-femoral joint in subjects with and without osteoarthritis during a 1-year follow-up. Osteoarthritis Cartilage 2007; 15: 1225-1234. (Pubitemid 350029045)
23. Dardzinski BJ, Mosher TJ, Li S, Van Slyke MA, Smith MB,. Spatial variation of T2 in human articular cartilage. Radiology 1997; 205: 546-550. (Pubitemid 27467340)
24. Riek JK, Ashton EA,. Use of a dual-echo fast-spin-echo sequence for T2 mapping of cartilage within a clinical trial. In: Proceedings of the 17th Annual Meeting of ISMRM, Honolulu, 2009. (abstract 3988).
25. Mosher TJ, Zhang Z, Reddy R, et al. Knee articular cartilage damage in osteoarthritis: analysis of MR image biomarker reproducibility in ACRIN-PA 4001 multicenter trial. Radiology 2011; 258: 832-842.
26. Lammentausta E, Multanen J, Nieminen MT,. Differences in T2 values of knee cartilage measured with different scanners. In: Proceedings of the 17th Annual Meeting of ISMRM, Honolulu, 2009. (abstract 3987).
27. Riek JK,. Using T2 phantoms to obtain consistent T2 relaxation times regardless of pulse sequence. Osteoarthritis Cartilage 2010; 18 (Suppl 2): S195-S196.
28. Ashton E, Durkin E, Kwok E, Evelhoch J,. Conversion From signal intensity to Gd concentration may be unnecessary for perfusion assessment of tumors using DCE-MRI. In: Proceedings of the 15th Annual Meeting of ISMRM, Berlin, 2007. (abstract 2813).
29. Evelhoch J,. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 1999; 10: 254-259. (Pubitemid 29463107)
30. Chu B, Zhao X, Saam T, et al. Feasibility of in vivo, multicontrast-weighted MR imaging of carotid atherosclerosis for multicenter studies. J Magn Reson Imaging 2005; 21: 809-817. (Pubitemid 40770874)
31. Lieberman J, Tollefson G, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005; 62: 361-370. (Pubitemid 40471685)
32. Bakshi R, Benedict R, Bermel R, et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis. Arch Neurol 2002; 59: 62-68.
33. Ashton E,. Widespread functional and molecular imaging in drug development. Expert Opin Drug Discov 2007; 2: 1477-1485. (Pubitemid 350186600)
34. Ashton E,. Quantitative medical imaging. J Imaging Sci Technol 2007; 51: 117-121. (Pubitemid 46945102)
35. Eckstein F, Westhoff J, Sittek H, et al. In vivo reproducibility of three-dimensional cartilage volume and thickness measurements with MR imaging. AJR Am J Roentgenol 1998; 170: 593-597. (Pubitemid 28106642)
36. Dunn TC, Lu Y, Jin H, Ries MD, Majumdar S,. T2 relaxation time of cartilage at MR imaging: comparison with severity of knee osteoarthritis. Radiology 2004; 232: 592-598. (Pubitemid 38971304)
37. Goodwin DW, Wadghiri YZ, Zhu H, Vinton CJ, Smith ED, Dunn JF,. Macroscopic structure of articular cartilage of the tibial plateau: influence of a characteristic matrix architecture on MRI appearance. AJR Am J Roentgenol 2004; 182: 311-318. (Pubitemid 38116568)
38. Stahl R, Blumenkrantz G, Carballido-Gamio J, et al. MRI-derived T2 relaxation times and cartilage morphometry of the tibio-femoral joint in subjects with and without osteoarthritis during a 1-year follow-up. Osteoarthritis Cartilage 2007; 15: 1225-1234. (Pubitemid 350029045)
39. Dardzinski BJ, Mosher TJ, Li S, Van Slyke MA, Smith MB,. Spatial variation of T2 in human articular cartilage. Radiology 1997; 205: 546-550. (Pubitemid 27467340)
40. Domayer SE, Kutscha-Lissberg F, Welsch G, et al. T2 mapping in the knee after microfracture at 3.0T: correlation of global T2 values and clinical outcome-preliminary results. Osteoarthritis Cartilage 2008; 16: 903-908.
41. Kurkijarvi JE, Mattila L, Ojala RO, et al. Evaluation of cartilage repair in the distal femur after autologous chondrocyte transplantation using T2 relaxation time and dGEMRIC. Osteoarthritis Cartilage 2007; 15: 372-378. (Pubitemid 46381566)
42. Maier CF, Tan SG, Hariharan H, Potter HG,. T2 quantitation of articular cartilage at 1.5 T. J Magn Reson Imaging 2003; 17: 358-364. (Pubitemid 36259251)
43. Marlovits S, Singer P, Zeller P, Mandl I, Haller J, Trattnig S,. Magnetic resonance observation of cartilage repair tissue (MOCART) for the evaluation of autologous chondrocyte transplantation: determination of interobserver variability and correlation to clinical outcome after 2 years. Eur J Radiol 2006; 57: 16-23. (Pubitemid 43075405)
44. Marlovits S, Striessnig G, Resinger CT, et al. Definition of pertinent parameters for the evaluation of articular cartilage repair tissue with high-resolution magnetic resonance imaging. Eur J Radiol 2004; 52: 310-319. (Pubitemid 39491310)
45. Menezes NM, Gray ML, Hartke JR, Burstein D,. T2 and T1rho MRI in articular cartilage systems. Magn Reson Med 2004; 51: 503-509. (Pubitemid 38298663)
46. Smith HE, Mosher TJ, Dardzinski BJ, et al. Spatial variation in cartilage T2 of the knee. J Magn Reson Imaging 2001; 14: 50-55.
47. Trattnig S, Mamisch TC, Welsch GH, et al. Quantitative T2 mapping of matrix-associated autologous chondrocyte transplantation at 3 Tesla: an in vivo cross-sectional study. Investigative Radiology 2007; 42: 442-448. (Pubitemid 46788745)
48. Wayne JS, Kraft KA, Shields KJ, Yin C, Owen JR, Disler DG,. MR imaging of normal and matrix-depleted cartilage: correlation with biomechanical function and biochemical composition. Radiology 2003; 228: 493-499. (Pubitemid 36910093)
49. White LM, Sussman MS, Hurtig M, Probyn L, Tomlinson G, Kandel R,. Cartilage T2 assessment: differentiation of normal hyaline cartilage and reparative tissue after arthroscopic cartilage repair in equine subjects. Radiology 2006; 241: 407-414. (Pubitemid 44632886)
50. David-Vaudey E, Ghosh S, Ries M, Majumdar S,. T2 relaxation time measurements in osteoarthritis. Magn Reson Imaging 2004; 22: 673-682.
51. Welsch GH, Mamisch TC, Domayer SE, et al. Cartilage T2 assessment at 3-T MR imaging: in vivo differentiation of normal hyaline cartilage from reparative tissue after two cartilage repair procedures - initial experience. Radiology 2008; 247: 154-161.
52. Murase K,. Efficient method for calculating kinetic parameters using T1-weighted dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Med 2004; 51: 858-862. (Pubitemid 38420465)
53. Collins J,. Imaging and other biomarkers in early clinical studies: ones step at a time or re-engineering drug development? J Clin Oncol 2005; 23: 5417-5419.
54. Flaherty K, Rosen M, Heitjan D, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 2008; 7: 496-501. (Pubitemid 351847022)
55. Hahn O, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008; 26: 4572-4578.
56. Ashton E, Raunig D, Ng C, Kelcz F, McShane T, Evelhoch J,. Scan-rescan variability in perfusion assessment of tumors in MRI using both model and data-derived arterial input functions. J Magn Reson Imaging 2008; 28: 791-796.
57. Ashton E, McShane T, Evelhoch J,. Inter-operator variability in perfusion assessment of tumors in MRI using automated AIF detection. Med Image Comput Comput Assist Interv 2005; 3749: 451-458. (Pubitemid 43828282)
58. O'Connor J, Jackson A, Parker G, Jayson G,. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96: 189-195. (Pubitemid 46160619)
59. O'Regan D, Callaghan M, Wylezinska-Arridge M, et al. Liver fat content and T2*: simultaneous measurement by using breath-hold multiecho MR imaging at 3.0T-feasibility. Radiology 2008; 247: 550-557.
60. Bashir A, Gray M, Hartke J, Burstein D,. Nondestructive imaging of human cartilage glycosaminoglycan concentration by MRI. Magn Reson Med 1999; 41: 857-865. (Pubitemid 29211125)